Finepoint Capital LP Reduces Stock Holdings in argenx SE (NASDAQ:ARGX)

Finepoint Capital LP decreased its holdings in shares of argenx SE (NASDAQ:ARGX) by 2.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 52,928 shares of the company’s stock after selling 1,500 shares during the period. argenx comprises 2.0% of Finepoint Capital LP’s portfolio, making the stock its 4th largest holding. Finepoint Capital LP’s holdings in argenx were worth $32,551,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ARGX. Whipplewood Advisors LLC bought a new position in argenx in the 4th quarter worth about $37,000. Global Retirement Partners LLC lifted its stake in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after buying an additional 61 shares during the last quarter. Huntington National Bank increased its position in shares of argenx by 1,133.3% during the fourth quarter. Huntington National Bank now owns 74 shares of the company’s stock valued at $46,000 after acquiring an additional 68 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after acquiring an additional 33 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of ARGX stock opened at $555.11 on Friday. The company has a market cap of $33.73 billion, a PE ratio of -630.81 and a beta of 0.60. The stock’s 50 day simple moving average is $621.43 and its two-hundred day simple moving average is $603.18. argenx SE has a 1 year low of $352.77 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities research analysts expect that argenx SE will post 3.13 EPS for the current year.

Analyst Upgrades and Downgrades

ARGX has been the subject of a number of research analyst reports. Oppenheimer lifted their target price on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. HC Wainwright upped their target price on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Citigroup reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. Finally, Wells Fargo & Company lifted their target price on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.